Relias Media - Continuing Medical Education Publishing

The trusted source for

healthcare information and

CONTINUING EDUCATION.

  • Sign In
  • Sign Out
  • MyAHC
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Live Webinars
      • On-Demand Webinars
      • Libraries
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Live Webinars
      • On-Demand Webinars
      • Libraries
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Live Webinars
      • On-Demand Webinars
    • All Access
      • Learn More
      • My Subscription
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    Home » Fluoroquinolone-Resistant Gonorrhea on the Rise: Exposure History is Critical

    Fluoroquinolone-Resistant Gonorrhea on the Rise: Exposure History is Critical

    July 1, 2004
    No Comments
    Reprints
    Facebook Twitter Linkedin Share Share
    Fluoroquinolone-Resistant Gonorrhea on the Rise: Exposure History is Critical

    Abstract & Commentary

    Source: Centers for Disease Control. Increases in Fluoroquinolone-Resistant Neisseria gonorrhoeae Among Men Who Have Sex with Men — United States, 2003, and Revised Recommendations for Gonorrhea Treatment, 2004. Morb Mort Wkly Rep MMWR 2004; 53;335-336.

    The Centers for Disease Control and Prevention (CDC) support ongoing surveillance of antibiotic susceptibilities of Neisseria gonorrhea isolates obtained from individuals presenting to sexually transmitted disease clinics in multiple U.S. locations. Preliminary data from the first nine months of 2003 suggest that the prevalence of fluoroquinolone (FQ) resistance among all gonorrhea isolates was 4.2%, compared with 2.2% in 2002 and 0.7% in 2001. Excluding Hawaii and California, the prevalence of FQ-resistant gonorrhea in men was just under 1% in 2003. However, among men who have sex with men (MSM), the prevalence of FQ-resistance gonorrhea was 4.9% in 2003, compared with 1.8% for the prior year.

    Because the prevalence of FQ-resistant gonorrhea isolates now approaches 5% among MSM, the CDC no longer recommends FQ therapy for treating gonorrhea in this population. This parallels the CDC’s recommendations for treating gonorrhea in both MSM and heterosexuals when infections were acquired in California, Hawaii, and Asia.

    Commentary by David J. Karras, MD, FAAEM, FACEP

    Oral agents largely have replaced the use of intramuscular antibiotics in treating gonococcal urethritis and cervicitis. Because cefixime (an oral, third-generation cephalosporin) has been unavailable for the past few years, FQs have been the drugs of choice. In 2002, the CDC reported that the prevalence of FQ-resistant gonorrhea had reached 5% among patients with infections acquired in Asia, the Pacific Islands (including Hawaii), and California. This level of resistance generally is used as the threshold for a change in therapy. The CDC, therefore, recommended that FQs no longer be used to treat infections acquired in these regions.

    It was inevitable that FQ-resistant gonorrhea would extend beyond these specific geographic areas. The CDC now recommends ceftriaxone 125 mg intramuscularly (IM) as the preferred therapy for gonococcal urethritis acquired in these endemic regions and in all MSM; spectinomycin 2 g IM is the alternative. Unless co-infection with chlamydia has been ruled out, concomitant therapy with doxycycline or azithromycin also is necessary.

    FQ therapy still may be appropriate for heterosexual patients outside the endemic regions. The CDC urges that practitioners obtain a careful travel and exposure history in patients with urethritis, and that they obtain gonorrhea cultures in cases of treatment failure to exclude the possibility of a drug-resistant infection.

    Fortunately, cefixime soon may again become available, and will be an acceptable oral therapeutic option for infections in MSM and in areas with high rates of FQ-resistant gonorrhea.

    Dr. Karras, Associate Professor of Emergency Medicine, Associate Chair for Academic Affairs, and Research Director, Department of Emergency Medicine, Temple University School of Medicine, Philadelphia, PA, is on the editorial board of Emergency Medicine Alert.

    Post a comment to this article

    Report Abusive Comment

    Practical Summaries in Acute Care Archives

    View PDF
    Emergency Medicine Alert 2004-07-01
    July 1, 2004

    Table Of Contents

    Code Stroke Protocol

    Septic Joint Difficult to Exclude by Laboratory Tests

    Fluoroquinolone-Resistant Gonorrhea on the Rise: Exposure History is Critical

    BNP: A Hearty Diagnostic Complement to the Chest Film in Heart Failure

    Special Feature: Radiologic Hazards and Acute Radiation Exposure

    ECG Review: Chest Pain in a 21-Year-Old

    Trauma Reports Supplement

    Shop Now: Search Products

    • Subscription Publications
    • Books & Study Guides
    • Webinars
    • Group & Site
      Licenses
    • State CME/CE
      Requirements

    Webinars And Events

    View All Events

    Free Email Newsletters

    All Fields Required

    E-Newsletter Options
    • Accreditation Council for Continuing Medical Education
    • American Nurses Credentialing Center
    • American College of Emergency Physician
    • American Board of Internal Medicine: Maintenance of Certification
    • California Board of Registered Nursing
    • Commission for Case Manager Certification
    • American Academy of Pediatrics
    • American Osteopathic Association
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Live Webinars
      • On-Demand Webinars
      • Libraries
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Live Webinars
      • On-Demand Webinars
      • Libraries
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Live Webinars
      • On-Demand Webinars
    • All Access
      • Learn More
      • My Subscription
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    • Help
    • Search
    • About Us
    • Sign In
    • Register
    Relias Media - Continuing Medical Education Publishing

    The trusted source for

    healthcare information and

    CONTINUING EDUCATION.

    Customer Service

    customerservice@reliasmedia.com

    U.S. and Canada: 1-800-688-2421

    International +1-404-262-5476

    Accounts Receivable

    1-800-370-9210
    ReliasMedia_AR@reliasmedia.com

    Mailing Address

    • 1010 Sync St., Suite 100
      Morrisville, NC 27560-5468
      USA

    © 2019 Relias. All rights reserved.

    Privacy Policy  Terms of Use  Contact Us  Reprints  Group Sales

    For DSR inquiries or complaints, please reach out to Wes Vaux, Data Privacy Officer, DPO@relias.com

    Design, CMS, Hosting & Web Development :: ePublishing